Bello Nicholas R, Wang Robert C, Boss Joseph, Singer Michael, Hopkins Sophia, Billawala Kiran, Henry Christopher R, Mammo Danny A
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Texas Retina Associates, Dallas, TX, USA.
J Vitreoretin Dis. 2025 Aug 20:24741264251365386. doi: 10.1177/24741264251365386.
To examine the effect of suprachoroidal triamcinolone acetonide on intraocular pressure (IOP) in patients with a known history of glaucoma, ocular hypertension, or steroid response. This was a multicenter, retrospective cohort study examining patients with glaucoma, ocular hypertension, or a prior steroid response who received suprachoroidal triamcinolone acetonide between February 1, 2022, and December 31, 2023. Patient charts were reviewed to record IOP at the time of treatment with suprachoroidal triamcinolone acetonide and at follow-up. Ten (17%) of 59 eyes experienced an IOP increase of 5 mm Hg or greater following suprachoroidal triamcinolone acetonide injection. At follow-up, 3 eyes (5%) were documented to have an IOP of greater than 25 mm Hg, and no eyes were found to have an IOP greater than 35 mm Hg. Notably, 30 (79%) of 38 eyes with a prior steroid response did not develop an IOP elevation of 5 mm Hg or higher. When removing eyes that had prior incisional glaucoma surgery, 17 (68%) of 25 eyes with prior steroid response still did not develop an IOP elevation of 5 mm Hg or greater. No eyes in this study required glaucoma surgery following suprachoroidal triamcinolone acetonide within the follow-up period. The mean follow-up from initial suprachoroidal triamcinolone acetonide to first visit was 42.0 days. This study examined patients who would be considered high-risk for intraocular steroid therapy. In this population, there was a lower tendency to have an IOP response following suprachoroidal triamcinolone acetonide compared with published rates of IOP elevation from intraocular steroids in eyes without a known steroid response. All patients receiving local corticosteroids should be monitored for IOP elevations.
为研究脉络膜上腔注射曲安奈德对有青光眼、高眼压或类固醇反应病史患者眼压（IOP）的影响。这是一项多中心回顾性队列研究，研究对象为2022年2月1日至2023年12月31日期间接受脉络膜上腔注射曲安奈德的青光眼、高眼压或既往有类固醇反应的患者。查阅患者病历，记录脉络膜上腔注射曲安奈德治疗时及随访时的眼压。59只眼中有10只（17%）在脉络膜上腔注射曲安奈德后眼压升高5 mmHg或更高。随访时，有3只眼（5%）记录眼压大于25 mmHg，未发现眼压大于35 mmHg的眼。值得注意的是，38只既往有类固醇反应的眼中有30只（79%）眼压升高未达5 mmHg或更高。去除既往有切口性青光眼手术史的眼后，25只既往有类固醇反应的眼中仍有17只（68%）眼压升高未达5 mmHg或更高。本研究中在随访期内没有眼在脉络膜上腔注射曲安奈德后需要进行青光眼手术。从首次脉络膜上腔注射曲安奈德到首次就诊的平均随访时间为42.0天。本研究检查了被认为是眼内类固醇治疗高风险的患者。在该人群中，与无已知类固醇反应的眼中眼内类固醇引起的眼压升高公布率相比，脉络膜上腔注射曲安奈德后眼压反应的趋势较低。所有接受局部皮质类固醇治疗的患者都应监测眼压升高情况。
